AR and prostate cancer: Also, in castrate-sensitive prostate cancer patients, who showed a significant percentage of AR-V7 positivity, an antibody dilution of 1:50 was used and demonstrated significant cytoplasmic staining, which is inconsistent with the nuclear location of AR-V7 (114).